2023 World Conference on Lung Cancer (Posters)-EP12.01. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE)

EP12.01. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) - PDF(Abstract)

Back to course

Pdf Summary

A recent study, called ARISE, evaluated the efficacy and safety of the third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) aumolertinib as a first-line treatment for patients with EGFR-mutant adenosquamous carcinoma (ASC). The study included treatment-naïve patients with locally advanced or metastatic pulmonary ASC and sensitive EGFR mutations. A total of 12 patients were enrolled, and the study was closed prematurely due to slow enrollment.<br /><br />The primary endpoint of the study was progression-free survival (PFS), and secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), intracranial ORR (iORR), intracranial DCR (iDCR), intracranial PFS (iPFS), and safety.<br /><br />At the data cutoff, 7 out of 12 patients achieved a partial response, resulting in an ORR of 58.3% and a DCR of 83.3%. Among the patients with central nervous system (CNS) metastases at baseline, one patient achieved a complete response in the brain. The median PFS was 6.2 months, and the median OS was not reached.<br /><br />Treatment-related adverse events (TRAEs) of any grade occurred in 63.6% of patients. The most common TRAEs were anemia and increased aspartate aminotransferase.<br /><br />The study concluded that aumolertinib has promising antitumor activity with a manageable toxicity profile for patients with EGFR-mutant ASC. This suggests that third-generation EGFR-TKIs can be used in the clinical practice of treating EGFR-mutant ASC.

Asset Subtitle

Gen Lin

Meta Tag

Speaker Gen Lin

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

ARISE

aumolertinib

EGFR-TKI

EGFR-mutant adenosquamous carcinoma

PFS

ORR

DCR

CNS metastases

TRAEs

antitumor activity